Advances in selectivity, safety, and patient convenience, oral small molecule drugs continue to be a key focus in drug development. Here, Dr Andreas Muehler and Daniel Vitt, PhD, the co-founders of Immunic Therapeutics, discuss the potential of Vidofludimus calcium as a breakthrough treatment for autoimmune diseases.
What are the main trends or recent advances in oral small molecule drug development?
Daniel Vitt (DV): A current trend in oral small molecule drug development is a shift towards creating more selective and patient-friendly drugs. Vidofludimus calcium (IMU-838), a drug developed by Immunic Therapeutics, is a prime example of this. It is highly selective and has shown an excellent safety and tolerability profile to date.
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
Learn about ITM’s implementation journey and considerations when evaluating the technology
Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry –Register for FREE
Can’t attend live? No worries – register to receive the recording post-event.
Advancements in oral small molecule drug development can be attributed to significant technological improvements, particularly in screening methodologies, including AI-driven approaches, which help identify and profile drugs more effectively. Despite the rise of newer, more complex treatment technologies, small molecules continue to play a crucial role due to their simplicity, ease of management, patient convenience and cost-effective production.
What are the biggest current challenges in developing oral small molecule drugs? What approach should the pharmaceutical industry take to address these issues?
DV: The challenges associated with the development of oral small molecule drugs are closely tied to the need for selectivity. The goal is to create a molecule that effectively targets its intended mechanism without affecting other biological pathways. In addition to selectivity, these drugs must exhibit favourable pharmaceutical properties, such as efficient metabolism, optimal exposure and ease of administration, ensuring they are both user-friendly and effective for patients.
While the pharmaceutical industry has made advancements in this area, there is concern that some companies may be shifting their focus towards emerging technologies, whose long-term value may be unclear and not cost-efficient. Despite this shift, the development of small molecules remains a highly promising avenue, especially for smaller companies in a space traditionally dominated by large pharmaceutical firms.
When compared to existing treatments, what makes Vidofludimus calcium a promising candidate for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis?
Andreas Muehler (AM): While it is challenging to compare Vidofludimus calcium across different indications such as multiple sclerosis (MS) and ulcerative colitis, there are several important commonalities. One of the key advantages of Vidofludimus calcium is its safety and tolerability profile, which is comparable to that of a placebo – something rarely seen for drugs treating chronic inflammatory or autoimmune diseases.
One of the key advantages of Vidofludimus calcium is its safety and tolerability profile, which is comparable to that of a placebo – something rarely seen for drugs treating chronic inflammatory or autoimmune diseases”
Typically, such treatments suppress the immune system to alleviate the damage caused by autoimmune diseases. Although effective, this approach often results in significant side effects, including increased susceptibility to viral reactivation, infections, and, in some cases, a heightened risk of cancer due to reduced immune surveillance.1
Vidofludimus calcium targets the enzyme dihydroorotate dehydrogenase (DHODH), which plays a specific role in metabolically activated immune cells involved in autoimmune diseases, without broadly affecting the immune system as a whole.
This selectivity allows it to suppress the immune system’s harmful activity without inhibiting its ability to fight infections or cancers. Additionally, preclinical data showed that Vidofludimus calcium potently activates the neuroprotective transcription factor nuclear receptor related 1 (Nurr1), which is associated with direct neuroprotective properties and may enhance the potential benefit for patients.
In clinical trials, patients treated with Vidofludimus calcium did not show increased rates of infections or infestations compared to placebo. Furthermore, other DHODH inhibitors had previously been shown to not interfere with the immune system’s response to vaccinations, allowing patients to generate a robust antibody response.
These factors make Vidofludimus calcium a highly promising candidate for the long-term treatment of chronic inflammatory and autoimmune diseases, potentially offering both efficacy and a superior safety and tolerability profile compared to traditional immunosuppressive therapies.
Furthermore, the key consideration for Vidofludimus calcium is that the definitive proof of its efficacy and safety requires the completion of Phase III studies. We believe our currently ongoing twin Phase III trials in relapsing multiple sclerosis are relatively low risk. This is because the trials’ primary endpoint – relapse activity – is closely linked to magnetic resonance imaging (MRI) lesions in these patients, for which a statistically significant effect was already shown in our previous Phase III EMPhASIS trial in relapsing-remitting MS.
In clinical trials, Vidofludimus calcium has shown a greater than 75 percent reduction in MRI lesions, which correlates strongly with a reduction in relapses”
MRI lesions are caused by brain tissue damage. While not every MRI lesion leads to a relapse in disease, nearly all relapses are associated with some form of brain lesion. In clinical trials, Vidofludimus calcium has shown a greater than 75 percent reduction in MRI lesions, which correlates strongly with a reduction in relapses.2
Given these findings, we are optimistic that the reduction in MRI lesions will directly translate to fewer relapses, making these studies relatively low risk. However, the final confirmation of safety, efficacy and the overall benefit-risk profile will come with the completion of the Phase III trials, which remains the most important milestone at this stage.
Can you highlight some of the key data for Vidofludimus calcium from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference? What impact could this have on the future development of small molecule drugs in the sector?
AM: We presented four abstracts at The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 congress, each highlighting different aspects of Vidofludimus calcium in MS. The first, a clinical abstract, focuses on the interim analysis from our Phase II CALIPER trial in progressive MS.3
The data showed that Vidofludimus calcium noticeably reduced neurofilament light chain, a biomarker of neuronal damage, compared to placebo. This suggests that the treatment could offer an effective protection of neurons. What is particularly important is that this effect is consistent across different subgroups of patients, regardless of age or disability levels, indicating broad efficacy across all progressive multiple sclerosis subtypes.
The second abstract investigates the relationship between Epstein-Barr Virus (EBV) reactivation and fatigue in MS patients. It links the reduction of EBV reactivations with potential alleviation of MS-related fatigue, a common and debilitating symptom that currently lacks effective treatment options. We believe Vidofludimus calcium could represent a promising new symptomatic therapy for MS fatigue. This aspect is currently being investigated in all our ongoing multiple sclerosis trials.
The third abstract explores neuroprotective mechanisms related to Nurr1 activation, demonstrating how Vidofludimus calcium seems to protect neurons by reducing the activity of microglial cells and thereby improving the neurotoxic environment around nerve cells. Additionally, it appears to reduce apoptosis (programmed cell death) enhancing neuronal survival under stressful conditions.
The fourth abstract focuses on the drug’s impact on T helper cells (Th cells), which play a critical role in the activation of the immune system and can contribute to the pathology of MS. This research delves into the immunological mechanisms behind Vidofludimus calcium’s effectiveness, emphasising how the drug modulates these cells to support its overall therapeutic effect.
Collectively, these findings highlight the potential of Vidofludimus calcium to not only slow MS disease progression but also address significant symptoms such as fatigue. This data could have a profound impact on the future development of small molecule drugs within the field of neurology.4
What developments in oral small molecule drugs do you anticipate over the next five to 10 years?
DV: One significant trend is the increasing emphasis on the ability of these drugs to penetrate cells. Unlike antibodies, which typically interact with cell surfaces, small molecules can enter cells, opening up new therapeutic possibilities, particularly in the central nervous system. Designing small molecules that can effectively cross the blood-brain barrier could lead to substantial advancements in treating central nervous system disorders.
the success of glucagon-like peptide 1 (GLP-1) agonists has demonstrated the potential for small molecules to replicate similar effects”
The pharmaceutical industry is also shifting its focus from oncology, which has been a dominant area of research, to other widespread and impactful conditions such as inflammatory and autoimmune diseases. These areas, including neurology and inflammatory conditions, present significant unmet needs, and we expect to see a surge in the development of oral small molecules targeting these conditions.
Additionally, the success of glucagon-like peptide 1 (GLP-1) agonists has demonstrated the potential for small molecules to replicate similar effects. Developing oral small molecules with comparable benefits could improve patient adherence and reduce healthcare costs.5
Overall, these trends suggest a future where oral small molecules play an increasingly vital role in addressing a wide range of medical conditions, from CNS disorders to inflammatory diseases, offering new treatment options and improving patient care.
About the interviewees
Daniel Vitt, PhD, is Co-Founder, President and CEO of Immunic Therapeutics, a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
Dr Andreas Muehler, MBA, is Co-Founder and Chief Medical Officer at Immunic Therapeutics.
References
Fox RJ, Heinz Wiendl, Wolf C, et al. Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation. 2024; 11(3).
Fox RJ, Heinz Wiendl, Wolf C, et al. A Double‐Blind, Randomized, Placebo‐Controlled Phase 2 Trial Evaluating The Selective Dihydroorotate Dehydrogenase Inhibitor Vidofludimus Calcium In Relapsing‐Remitting Multiple Sclerosis. Annals of Clinical and Translational Neurology. 2022; 9(7):977–87.
Immunic, Inc. Today Announced That Data From Its Phase 2 Emphasis Trial [Internet] Immunic Therapeutics. 2024. [cited 2024Oct]. Available from: https://imux.com/immunic-announces-publication-of-extended-data-from-phase-2-emphasis-trial-of-vidofludimus-calcium-in-relapsing-remitting-multiple-sclerosis-in-the-peer-reviewed-journal/
Immunic, Inc. Today Announced The Presentation Of Key Data At The 40th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis (ECTRIMS) [Internet] Immunic Therapeutics. 2024. [cited 2024Oct]. Available from: https://imux.com/immunic-presents-key-vidofludimus-calcium-data-at-the-40th-congress-of-ectrims-highlighting-its-therapeutic-potential-in-multiple-sclerosis/
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 Receptor Agonists In The Treatment Of Type 2 Diabetes – State-Of-The-Art.. [Internet] Molecular Metabolism. 2021; 46(46):101102.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.